How to Pick the Right CDMO: The Definitive Playbook for Pharma IP Teams, Portfolio Managers, and R&D Leads
Executive Summary The global CDMO market hit USD 238.92 billion in 2024 and is on track to reach USD 465.24 […]
August 2023
Strategies to Maximize Product Value Amid Loss of Exclusivity in the Pharmaceutical Industry
The Inevitable Horizon: Understanding Loss of Exclusivity (LOE) The pharmaceutical landscape is characterized by cycles of innovation, market exclusivity, and
Why Biosimilar Filings Fail: The Complete Technical Guide to 351(k) Rejections, CRL Patterns, and CMC Pitfalls
1. The Stakes: What a Failed 351(k) Filing Actually Costs A Complete Response Letter (CRL) is not an administrative inconvenience.
Artificial Intelligence and Machine Learning in Drug Discovery and Development
The pharmaceutical industry is on the brink of a revolution. Artificial Intelligence (AI) and Machine Learning (ML) are emerging as
Artificial Intelligence and Machine Learning in Drug Discovery and Development Read Post »
Prevalence and timing of authorized generics in the US market
The rise of authorized generics has become a defining feature of U.S. pharmaceutical markets in the past decade. In plain
Prevalence and timing of authorized generics in the US market Read Post »
Insights into Shifting Dynamics: Orange Book and Biologic PTAB Trends
The last five years have seen seismic shifts in how pharmaceutical patent disputes are fought – and the trends have
Insights into Shifting Dynamics: Orange Book and Biologic PTAB Trends Read Post »
The Evolution of Reverse Payment Cases: Courts and Agencies’ Approaches in Pharma Litigation
Introduction: Unpacking the “Pay-for-Delay” Phenomenon The intricate world of pharmaceutical patent litigation is a battleground where innovation, competition, and public
Authorized Generics: The Brand’s Last Weapon Against Generic Entry (And What It Costs Everyone Else)
Section 1: What an Authorized Generic Actually Is (And Why Definitions Matter for Deal Modeling) 1.1 The Core Definition An
